论文部分内容阅读
《新编药物学》(第十版)是一本内容丰富的药物学书籍,其优点前文[徐永昭:本刊13(2):92,1978]多已谈到,不赘。现就书中存在的缺点和错误补充几点,供有关方面参考。一、内容错误和欠妥当的地方1.379页甲多巴“本品为脱羧酶抑制剂,通过抑制儿茶酚胺的合成速度,降低组织内去甲肾上腺素的含量因而使血压下降”。目前已不同意此种说法。甲多巴虽为脱羧酶抑制剂,但一般认为其降压作用与抑制脱羧酶无关。Gillespie 等在高血压患者中,应用两种很强的脱羧酶抑制剂,并无降压效果。甚至象DL-α甲基儿茶酚丙肼酸,体外脱羧酶抑制力比甲多
The New Pharmacology (tenth edition) is an informative book on pharmacology. The advantages of the former [Xu Yongzhao: 13 (2): 92, 1978] have already been talked about. Now on the book shortcomings and errors to add a few points for reference. First, the contents of the error and improper place 1.379 Cadeba “This product is a decarboxylase inhibitor, by inhibiting the synthesis rate of catecholamines, reducing the content of norepinephrine in the tissue thus reducing blood pressure ”. Now disagree with this statement. Although methadone is a decarboxylase inhibitor, it is generally believed that its antihypertensive effect is not related to inhibition of decarboxylase. Gillespie and other hypertensive patients, the application of two strong decarboxylase inhibitors, no antihypertensive effect. Even DL-α-methyl catechin hydrazide acid, in vitro decarboxylase inhibition more than a